Physician profile
Bryan A Smith
NPI 1982914990
$8,579.19
in general payments reported to CMS, 2019-2025
23 companies · $50.03 in 2025
The $50.03 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,385 · 2020: $831 · 2021: $389 · 2022: $5,491 · 2023: $433 · 2025: $50.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $482.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $4,844.10 | 2019-2023 | |
| Abbott Laboratories | $2,259.64 | 2019-2023 | Xience Sierra, Thoratec Heartmate 3 Lvas Implant Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $494.21 | 2019-2023 | Lifevest |
| Medtronic Vascular, INC. | $183.09 | 2019 | |
| Cvrx, INC. | $171.32 | 2021 | |
| Novo Nordisk INC | $117.15 | 2022 | |
| Novartis Pharmaceuticals Corporation | $67.14 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $55.95 | 2022-2023 | Brilinta |
| Amgen INC. | $47.47 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.37 | 2023-2025 | Jardiance |
| Zoll Circulation INC | $35.32 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $34.40 | 2023 | Camzyos |
| Bridgebio Pharma, INC. | $29.27 | 2025 | Attruby |
| Portola Pharmaceuticals, LLC | $26.83 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $24.47 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $23.62 | 2022 | |
| United Therapeutics Corporation | $21.96 | 2019 | |
| Akcea Therapeutics, INC. | $21.39 | 2019 | |
| Lantheus Medical Imaging, INC. | $21.03 | 2023 | Definity |
| Merck Sharp & Dohme LLC | $20.56 | 2022 | |
| Kerecis Limited | $17.82 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Arbor Pharmaceuticals, INC. | $14.25 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.